JPMorgan Chase & Co. Cuts Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $20.00

Agios Pharmaceuticals (NASDAQ:AGIO) had its price target reduced by JPMorgan Chase & Co. from $37.00 to $20.00 in a report published on Friday morning,Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the biopharmaceutical company’s stock.

AGIO has been the topic of a number of other research reports. Leerink Partnrs raised shares of Agios Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday. Royal Bank Of Canada cut shares of Agios Pharmaceuticals from an “outperform” rating to a “sector perform” rating and cut their price target for the stock from $57.00 to $28.00 in a research report on Wednesday, November 19th. Wall Street Zen raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. HC Wainwright dropped their target price on Agios Pharmaceuticals from $56.00 to $48.00 and set a “buy” rating on the stock in a report on Thursday. Finally, Leerink Partners upgraded Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating and decreased their price target for the company from $40.00 to $34.00 in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $36.00.

Agios Pharmaceuticals Trading Up 2.7%

Shares of Agios Pharmaceuticals stock opened at $25.24 on Friday. The company has a market capitalization of $1.47 billion, a PE ratio of -3.61 and a beta of 0.89. Agios Pharmaceuticals has a 12 month low of $22.24 and a 12 month high of $62.45. The stock’s fifty day simple moving average is $39.91 and its 200 day simple moving average is $36.91.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.78) EPS for the quarter, topping analysts’ consensus estimates of ($1.93) by $0.15. Agios Pharmaceuticals had a negative return on equity of 28.35% and a negative net margin of 895.86%.The company had revenue of $12.90 million for the quarter, compared to analyst estimates of $10.49 million. During the same quarter last year, the firm posted $16.22 earnings per share. Agios Pharmaceuticals’s revenue was up 43.3% compared to the same quarter last year. Analysts predict that Agios Pharmaceuticals will post -6.85 EPS for the current fiscal year.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, insider Sarah Gheuens sold 3,302 shares of the company’s stock in a transaction that occurred on Monday, October 27th. The shares were sold at an average price of $43.92, for a total transaction of $145,023.84. Following the completion of the sale, the insider owned 61,727 shares of the company’s stock, valued at approximately $2,711,049.84. This represents a 5.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Cecilia Jones sold 3,651 shares of the firm’s stock in a transaction on Friday, September 26th. The shares were sold at an average price of $36.77, for a total value of $134,247.27. Following the completion of the sale, the chief financial officer directly owned 33,870 shares in the company, valued at approximately $1,245,399.90. This represents a 9.73% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 16,099 shares of company stock valued at $620,092 in the last quarter. Company insiders own 4.93% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. NewEdge Advisors LLC bought a new stake in Agios Pharmaceuticals during the 1st quarter worth approximately $40,000. First Horizon Corp bought a new position in shares of Agios Pharmaceuticals during the third quarter worth about $45,000. CWM LLC lifted its stake in shares of Agios Pharmaceuticals by 150.2% in the first quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 996 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Agios Pharmaceuticals by 16.7% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,237 shares of the biopharmaceutical company’s stock valued at $74,000 after acquiring an additional 320 shares during the last quarter. Finally, Quantbot Technologies LP bought a new stake in Agios Pharmaceuticals in the third quarter valued at approximately $79,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.